Showing results (1-10 of 34) with videos related to
Sort By:
Pageof 4
International Journal of Molecular Sciences|November 17, 2019
Melanoma and Vitiligo: In Good CompanyCristina Maria Failla, Maria Luigia Carbone, Cristina Fortes, et al.Frontiers in Medicine|December 26, 2022
Case report: Bullous pemphigoid arising in a patient with scleroderma and multiple sclerosisFrancesco Moro, Feliciana Mariotti, Anna Pira, et al.European Journal of Pediatrics|July 18, 2021
Differences in individual and environmental factors between cutaneous melanoma and atypical Spitz tumour in children and adolescentsCristina Fortes, Simona Mastroeni, Maria Capuano, et al.Anticancer Research|August 19, 2007
Clinical and dermoscopic criteria related to melanoma sentinel lymph node positivityGianluca Pagnanelli, Riccardo Bono, Maria A Pizzichetta, et al.Drugs in Context|April 20, 2023
Effectiveness of risankizumab in the treatment of palmoplantar psoriasis: a 52-week Italian real-life experienceGiacomo Caldarola, Arianna Zangrilli, Gerardo Palmisano, et al.International Journal of Molecular Sciences|April 26, 2020
Multiple Sclerosis Treatment and Melanoma DevelopmentMaria Luigia Carbone, Pedro Miguel Lacal, Serena Messinese, et al.Plos One|May 1, 2020
Interleukin (IL)-17/IL-36 axis participates to the crosstalk between endothelial cells and keratinocytes during inflammatory skin responsesLaura Mercurio, Cristina M Failla, Lorena Capriotti, et al.Cell Death & Disease|November 1, 2018
IL-38 has an anti-inflammatory action in psoriasis and its expression correlates with disease severity and therapeutic response to anti-IL-17A treatmentLaura Mercurio, Martina Morelli, Claudia Scarponi, et al.International Journal of Dermatology|June 27, 2025
Effectiveness of Bimekizumab in Psoriatic Arthritis: A Multicenter Real-Life Study With Clinical and Ultrasound Evaluation in the Lazio Region, ItalyGiacomo Caldarola, Annunziata Dattola, Nicoletta Bernardini, et al.Journal of Personalized Medicine|December 27, 2024
Efficacy and Safety of Intra-Class Switching from Ixekizumab to Secukinumab in Patients with Plaque Psoriasis: A Multicenter Retrospective StudyNicoletta Bernardini, Annunziata Dattola, Raimondo Rossi, et al.Pageof 4